Inozyme Pharma, Inc. (INZY) Tops Q3 EPS by 5c

Inozyme Pharma, Inc. (NASDAQ: INZY) reported Q3 EPS of ($0.39), $0.05 better than the analyst estimate of ($0.44).

For earnings history and earnings-related data on Inozyme Pharma, Inc. (INZY) click here.

You May Also Be Interested In

• Walmart (WMT) Tops Q2 EPS by 7c, Beats on Revenue; Offers FY27 EPS Guidance
• Daqo New Energy (DQ) Misses Q2 EPS by 67c
• BofA Securities Starts ProQR Therapeutics N.V. (PRQR) at Buy